Turk Ilac ve Serumnayi (IST:TRILC) Stock Based Compensation: ₺0 Mil (TTM As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IST:TRILC Turk Ilac ve Serum Sanayi IST:TRILC
61 GF Score
Price ₺1.51
GF Value ₺3.63
Valuation Possible Value Trap
! 11 Warning Signs
View Full Analysis

What is Turk Ilac ve Serumnayi Stock Based Compensation?

Turk Ilac ve Serumnayi IST:TRILC +9.42% 61 Stock Based Compensation is ₺0 Mil as of Sep. 2025. GuruFocus rates IST:TRILC with a GF Score™ of 61/100 and a GF Value™ of ₺3.63 (Possible Value Trap). The stock has 11 warning signs investors should review.

Turk Ilac ve Serumnayi's Stock Based Compensation for the three months ended in Sep. 2025 was ₺0 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Sep. 2025 was ₺0 Mil.

Turk Ilac ve Serumnayi Stock Based Compensation Related Terms

Turk Ilac ve Serumnayi Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Turk Ilac ve Serumnayi's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Turk Ilac ve Serumnayi Stock Based Compensation Chart

Turk Ilac ve Serumnayi Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Stock Based Compensation
0.00 0.00 0.00 0.00 0.00

Turk Ilac ve Serumnayi Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
IST:TRILC
61GF Score
Turk Ilac ve Serum Sanayi IST:TRILC
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Turk Ilac ve Serumnayi Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₺0 Mil.

What does a Stock Based Compensation of ₺0 Mil mean?
Turk Ilac ve Serumnayi (IST:TRILC) has a Stock Based Compensation of ₺0 Mil as of Sep. 2025. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Turk Ilac ve Serumnayi and its competitors.
Is Turk Ilac ve Serumnayi's Stock Based Compensation too high?
Turk Ilac ve Serumnayi's current Stock Based Compensation is ₺0 Mil. Overall, Turk Ilac ve Serumnayi has a GF Score™ of 61/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Turk Ilac ve Serumnayi's Stock Based Compensation compare to ZTS and UTHR?
Turk Ilac ve Serumnayi's Stock Based Compensation of ₺0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Drug Manufacturers company?
A good Stock Based Compensation depends on the Drug Manufacturers industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Turk Ilac ve Serumnayi and its competitors. Turk Ilac ve Serumnayi's current Stock Based Compensation is ₺0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Turk Ilac ve Serumnayi stock overvalued right now?
Based on GuruFocus' analysis, Turk Ilac ve Serumnayi (IST:TRILC) is currently considered Possible Value Trap. The stock's GF Value™ is ₺3.63, compared to a current price of ₺1.51 — trading 58.4% below its estimated fair value. The current Stock Based Compensation is ₺0 Mil. Turk Ilac ve Serumnayi's overall GF Score™ is 61/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Turk Ilac ve Serumnayi (IST:TRILC), the current Stock Based Compensation is ₺0 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Turk Ilac ve Serumnayi (IST:TRILC) Overvalued in 2026?

Based on GuruFocus' analysis, Turk Ilac ve Serumnayi stock appears to be undervalued. The current stock price of ₺1.51 is trading 58.4% below its estimated GF Value™ of ₺3.63. GuruFocus considers Turk Ilac ve Serumnayi to be Possible Value Trap.

Key valuation signals for IST:TRILC:

  • Stock Based Compensation: ₺0 Mil
  • GF Value™: ₺3.63 vs. price of ₺1.51 (58.4% below fair value)
  • GF Score™: 61/100 with 11 warning signs

No single metric tells the full story. See the IST:TRILC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Turk Ilac ve Serumnayi Business Description

Address Bugduz Mahalle Enver Pasa Cadde, No: 8 Akyurt, Ankara, TUR, TR 06750
Turk Ilac ve Serum Sanayi is engaged in the production of human pharmaceuticals and vaccines.
61GF Score

Get the complete analysis for IST:TRILC

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₺1.51
Price
₺3.63
GF Value